Skip to main content

Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma

Buy Article:

$43.00 plus tax (Refund Policy)

Turunen N, Karihtala P, Mäntyniemi A, Sormunen R, Holmgren A, Kinnula VL, Soini Y. Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma. APMIS 2004;112:123–32.

We investigated the expression of thioredoxin and thioredoxin reductase in a large set of breast invasive and in situ carcinomas by immunohistochemistry. Additionally, NF-κB, p53 and proliferating cell nuclear antigen (PCNA) expression was studied. Thioredoxin and thioredoxin reductase expression was located in both cytoplasmic and nuclear compartments of the cell. Cytoplasmic thioredoxin positivity was found in 67 % and nuclear in 59 % of the cases, while thioredoxin reductase was found in 55 % and 6 % of cases, respectively. Ductal carcinomas showed stronger cytoplasmic thioredoxin immunoreactivity than lobular ones. Nuclear thioredoxin positivity was more often found in in situ lesions, and lobular carcinomas were more often negative than ductal ones. Both cytoplasmic and nuclear thioredoxin-positive cases had a high proliferation measured by PCNA staining. Positive nuclear immunostaining was associated with negative estrogen and progesterone receptor status. Cases with high p53 expression showed significantly higher nuclear thioredoxin positivity, but lower thioredoxin reductase positivity. Whilst thioredoxin or thioredoxin reductase was not associated with patient survival, cases showing both cytoplasmic and nuclear thioredoxin reductase-positive tumours had a shorter disease-free interval than those with negative immunostaining.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Breast cancer; immunohistochemistry; oxidative stress; p53; thioredoxin; thioredoxin reductase

Document Type: Research Article

Affiliations: 1: Department of Pathology, Oulu University Hospital; 2: Biocenter Oulu and Department of Pathology, University of Oulu, Finland 3: Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden 4: Department of Medicine, Division of Pulmonary Medicine, University of Helsinki and Helsinki University Hospital, Finland

Publication date: 2004-02-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more